|
private:innoventbiologics
|
4798582
|
May 29th, 2019 12:00AM
|
Innovent Biologics, Inc. 信达生物制药（苏州）有限公司
|
2.5K
|
267.00
|
Open
|
Pharmaceuticals
|
May 28th, 2019 11:49PM
|
May 28th, 2019 11:49PM
|
Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development.
Innovent has been recognized by government for its significant contributions in innovation. In January 2017, Innovent founder and CEO Michael Yu, was selected as State’s “Person of the Year in Innovation for Science and Technology in China in 2016”. The event was organized by eight ministries—Chinese Academy of Sciences, CCTV, Ministry of Science and Technology and etc. In June 2016, Innovent was invited to attend the National “12th Five-Year” Science and Technology Innovation Achievement Exhibition, where Innovent was widely recognized by national leaders. In 2015, Innovent’s R&D progress was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry”.
|
Open
|
Biologics Manufacturing, Monoclonal Antibodies, Biosimilars, Novel Drugs
|
Open
|
168 Dong Ping Street
|
Suzhou
|
Jiangsu
|
CN
|
215123
|
|
Innovent Biologics
|
Health Care
|
Health Care Equipment & Services
|
|
private:innoventbiologics
|
4798582
|
Feb 17th, 2018 12:00AM
|
Innovent Biologics, Inc. 信达生物制药（苏州）有限公司
|
1.7K
|
152.00
|
Open
|
Pharmaceuticals
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development.
Innovent has been recognized by government for its significant contributions in innovation. In January 2017, Innovent founder and CEO Michael Yu, was selected as State’s “Person of the Year in Innovation for Science and Technology in China in 2016”. The event was organized by eight ministries—Chinese Academy of Sciences, CCTV, Ministry of Science and Technology and etc. In June 2016, Innovent was invited to attend the National “12th Five-Year” Science and Technology Innovation Achievement Exhibition, where Innovent was widely recognized by national leaders. In 2015, Innovent’s R&D progress was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry”.
|
|
|
|
|
|
|
|
|
|
Innovent Biologics
|
Health Care
|
Health Care Equipment & Services
|
|
private:innoventbiologics
|
4798582
|
Feb 16th, 2018 12:00AM
|
Innovent Biologics, Inc. 信达生物制药（苏州）有限公司
|
1.7K
|
152.00
|
Open
|
Pharmaceuticals
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development.
Innovent has been recognized by government for its significant contributions in innovation. In January 2017, Innovent founder and CEO Michael Yu, was selected as State’s “Person of the Year in Innovation for Science and Technology in China in 2016”. The event was organized by eight ministries—Chinese Academy of Sciences, CCTV, Ministry of Science and Technology and etc. In June 2016, Innovent was invited to attend the National “12th Five-Year” Science and Technology Innovation Achievement Exhibition, where Innovent was widely recognized by national leaders. In 2015, Innovent’s R&D progress was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry”.
|
|
|
|
|
|
|
|
|
|
Innovent Biologics
|
Health Care
|
Health Care Equipment & Services
|
|
private:innoventbiologics
|
4798582
|
Feb 15th, 2018 12:00AM
|
Innovent Biologics, Inc. 信达生物制药（苏州）有限公司
|
1.7K
|
152.00
|
Open
|
Pharmaceuticals
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development.
Innovent has been recognized by government for its significant contributions in innovation. In January 2017, Innovent founder and CEO Michael Yu, was selected as State’s “Person of the Year in Innovation for Science and Technology in China in 2016”. The event was organized by eight ministries—Chinese Academy of Sciences, CCTV, Ministry of Science and Technology and etc. In June 2016, Innovent was invited to attend the National “12th Five-Year” Science and Technology Innovation Achievement Exhibition, where Innovent was widely recognized by national leaders. In 2015, Innovent’s R&D progress was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry”.
|
|
|
|
|
|
|
|
|
|
Innovent Biologics
|
Health Care
|
Health Care Equipment & Services
|
|
private:innoventbiologics
|
4798582
|
Feb 14th, 2018 12:00AM
|
Innovent Biologics, Inc. 信达生物制药（苏州）有限公司
|
1.7K
|
152.00
|
Open
|
Pharmaceuticals
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development.
Innovent has been recognized by government for its significant contributions in innovation. In January 2017, Innovent founder and CEO Michael Yu, was selected as State’s “Person of the Year in Innovation for Science and Technology in China in 2016”. The event was organized by eight ministries—Chinese Academy of Sciences, CCTV, Ministry of Science and Technology and etc. In June 2016, Innovent was invited to attend the National “12th Five-Year” Science and Technology Innovation Achievement Exhibition, where Innovent was widely recognized by national leaders. In 2015, Innovent’s R&D progress was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry”.
|
|
|
|
|
|
|
|
|
|
Innovent Biologics
|
Health Care
|
Health Care Equipment & Services
|
|
private:innoventbiologics
|
4798582
|
Feb 13th, 2018 12:00AM
|
Innovent Biologics, Inc. 信达生物制药（苏州）有限公司
|
1.7K
|
152.00
|
Open
|
Pharmaceuticals
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development.
Innovent has been recognized by government for its significant contributions in innovation. In January 2017, Innovent founder and CEO Michael Yu, was selected as State’s “Person of the Year in Innovation for Science and Technology in China in 2016”. The event was organized by eight ministries—Chinese Academy of Sciences, CCTV, Ministry of Science and Technology and etc. In June 2016, Innovent was invited to attend the National “12th Five-Year” Science and Technology Innovation Achievement Exhibition, where Innovent was widely recognized by national leaders. In 2015, Innovent’s R&D progress was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry”.
|
|
|
|
|
|
|
|
|
|
Innovent Biologics
|
Health Care
|
Health Care Equipment & Services
|
|
private:innoventbiologics
|
4798582
|
Feb 12th, 2018 12:00AM
|
Innovent Biologics, Inc. 信达生物制药（苏州）有限公司
|
1.7K
|
152.00
|
Open
|
Pharmaceuticals
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development.
Innovent has been recognized by government for its significant contributions in innovation. In January 2017, Innovent founder and CEO Michael Yu, was selected as State’s “Person of the Year in Innovation for Science and Technology in China in 2016”. The event was organized by eight ministries—Chinese Academy of Sciences, CCTV, Ministry of Science and Technology and etc. In June 2016, Innovent was invited to attend the National “12th Five-Year” Science and Technology Innovation Achievement Exhibition, where Innovent was widely recognized by national leaders. In 2015, Innovent’s R&D progress was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry”.
|
|
|
|
|
|
|
|
|
|
Innovent Biologics
|
Health Care
|
Health Care Equipment & Services
|
|
private:innoventbiologics
|
4798582
|
Feb 11th, 2018 12:00AM
|
Innovent Biologics, Inc. 信达生物制药（苏州）有限公司
|
1.7K
|
152.00
|
Open
|
Pharmaceuticals
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development.
Innovent has been recognized by government for its significant contributions in innovation. In January 2017, Innovent founder and CEO Michael Yu, was selected as State’s “Person of the Year in Innovation for Science and Technology in China in 2016”. The event was organized by eight ministries—Chinese Academy of Sciences, CCTV, Ministry of Science and Technology and etc. In June 2016, Innovent was invited to attend the National “12th Five-Year” Science and Technology Innovation Achievement Exhibition, where Innovent was widely recognized by national leaders. In 2015, Innovent’s R&D progress was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry”.
|
|
|
|
|
|
|
|
|
|
Innovent Biologics
|
Health Care
|
Health Care Equipment & Services
|
|
private:innoventbiologics
|
4798582
|
Feb 10th, 2018 12:00AM
|
Innovent Biologics, Inc. 信达生物制药（苏州）有限公司
|
1.7K
|
152.00
|
Open
|
Pharmaceuticals
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development.
Innovent has been recognized by government for its significant contributions in innovation. In January 2017, Innovent founder and CEO Michael Yu, was selected as State’s “Person of the Year in Innovation for Science and Technology in China in 2016”. The event was organized by eight ministries—Chinese Academy of Sciences, CCTV, Ministry of Science and Technology and etc. In June 2016, Innovent was invited to attend the National “12th Five-Year” Science and Technology Innovation Achievement Exhibition, where Innovent was widely recognized by national leaders. In 2015, Innovent’s R&D progress was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry”.
|
|
|
|
|
|
|
|
|
|
Innovent Biologics
|
Health Care
|
Health Care Equipment & Services
|
|
private:innoventbiologics
|
4798582
|
Feb 9th, 2018 12:00AM
|
Innovent Biologics, Inc. 信达生物制药（苏州）有限公司
|
1.7K
|
152.00
|
Open
|
Pharmaceuticals
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development.
Innovent has been recognized by government for its significant contributions in innovation. In January 2017, Innovent founder and CEO Michael Yu, was selected as State’s “Person of the Year in Innovation for Science and Technology in China in 2016”. The event was organized by eight ministries—Chinese Academy of Sciences, CCTV, Ministry of Science and Technology and etc. In June 2016, Innovent was invited to attend the National “12th Five-Year” Science and Technology Innovation Achievement Exhibition, where Innovent was widely recognized by national leaders. In 2015, Innovent’s R&D progress was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry”.
|
|
|
|
|
|
|
|
|
|
Innovent Biologics
|
Health Care
|
Health Care Equipment & Services
|